Neuvotion to Launch NeuStim AI-Guided Neuromodulation System Following Nature Medicine Breakthrough
Neuvotion, a Darien, Connecticut-based early-stage medical device company developing an AI-guided neuromodulation platform, is translating peer-reviewed research published in Nature Medicine into commercially available solutions designed to restore movement, sensation, and independence for patients with neurological injury and disease. The company’s Brain-Body Interface (BBI) portfolio integrates wearable high-resolution muscle stimulation, spinal neuromodulation, and minimally invasive brain-computer interface (BCI) technologies.
A landmark study published in Nature Medicine, led by Neuvotion founder and CEO Chad Bouton, PhD, during his tenure at the Feinstein Institutes for Medical Research, confirmed that a “double neural bypass” system can restore targeted areas of movement and sensation simultaneously in a person with complete paralysis, with lasting improvements. Over a three-year period of clinical testing, participant Keith Thomas regained the ability to feed himself, drink from a cup, and scratch his nose and wipe his face using his own hand — producing gains in arm strength of 86% on his right side and 62% on his left, gains that persisted for months after stimulation ended. Using a technique the research team calls “cortical mirroring,” Thomas also regained the ability to feel touch in his wrist, an area that had been completely without sensation since his injury. The system was precise enough to allow him to pick up and hold empty eggshells without breaking them 87% of the time.
Dr. Bouton said the study is the culmination of many years of work and is the first BCI to support recovery of both movement and sensation while promoting long-term gains. He noted that the system is not just bypassing the injury but “rewiring” the nervous system to promote neuroplasticity and help users regain sensation, get stronger, and regain independence — even after the system is turned off. Most brain-computer interfaces available today restore a single function — movement or communication — and rarely restore a sense of touch with lasting benefits.
Neuvotion is bringing this foundational science to market beginning with NeuStim, the first FDA-cleared product in its brain-body interface portfolio, launching this fall. NeuStim provides AI-guided high-resolution electrical stimulation non-invasively to muscles for promoting recovery after stroke and spinal cord injury. The system allows clinicians to set up quickly and pinpoint stimulation targets within minutes through a touch-screen interface that allows users to move the stimulation point electronically, eliminating manual electrode removal and replacement. The AI-guidance capability can infer user intentions and intuitively provide stimulation to assist with movements, all without requiring brain surgery.
The double neural bypass technology from Dr. Bouton’s lab was named to TIME’s Best Inventions of the Quarter Century Hall of Fame in 2025 and TIME’s Best Inventions list of 2024. Neuvotion is working with leading rehabilitation centers to expand clinical adoption of its products, bringing advanced neurorecovery from specialized research environments into everyday clinical care.
